Trace Biosciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Trace Biosciences is a clinical-stage biotech developing novel fluorescence imaging agents to visualize nerves intraoperatively, aiming to prevent the estimated 25 million nerve injuries that occur globally each year during surgery. The company's platform, built from a library of over 400 novel small-molecule fluorophores, has yielded its lead candidate, NerveTrace Dx, which has received FDA IND approval to begin clinical trials. With a seasoned leadership team and partnerships with top clinical institutions, Trace is positioned to address a significant unmet need in multiple surgical specialties, including orthopedic, reconstructive, and head & neck procedures.

Surgical ImagingNerve Injury Prevention

Technology Platform

Proprietary platform for developing targeted small-molecule fluorescent imaging agents that selectively bind to nerve tissue for real-time intraoperative visualization. Built from a library of over 400 novel fluorophores, designed for compatibility with existing clinical NIR imaging systems.

Opportunities

The massive unmet need to prevent ~25 million annual surgical nerve injuries creates a clear and large addressable market across numerous surgical specialties.

Successful clinical validation could lead to rapid adoption as a standard-of-care tool for precision surgery, with potential for partnership or acquisition by a larger medtech company.

Risk Factors

Primary risks include clinical trial failure in the newly initiated Phase I/II studies, regulatory hurdles beyond the IND stage, and competition from other groups developing nerve imaging solutions.

As a pre-revenue company, it also faces financing risk and future challenges in achieving surgeon adoption and favorable reimbursement.

Competitive Landscape

The competitive field for nerve-specific imaging is emerging but not yet crowded. Potential competitors include other biotechs developing fluorescent probes, academic research groups, and large medical imaging companies that could develop complementary hardware or software solutions. Trace's first-mover advantage with an IND-approved agent and its focus on small-molecule, system-compatible dyes are key differentiators.

More companies in Diagnostics & Precision Medicine →More companies in United States →